However, to date, noFDA-approved drug has targeted MDM2.8 Nevertheless,several drug candidates are in clinical trials, including nutlinsand its derivatives, such as ALRN-6924, SAR405838, NVP-CGM097, MK-8242,RG7112, RG7388, DS-3032b, and AMG232.9−11 These drugs are allbased on the MDM2 inhibition mechanism and have shown promising resultsin preclinical and early clinical trials, suggesting the potentialof targeting the MDM2–p53 axis as a promising therapeutic strategyfor cancer treatment. This evidence concerns the gene TP53 and cancer.